RPG Life Sciences Limited (RPGLIFE) - Total Assets
Based on the latest financial reports, RPG Life Sciences Limited (RPGLIFE) holds total assets worth Rs7.06 Billion INR (≈ $76.32 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See RPG Life Sciences Limited book value and equity for net asset value and shareholders' equity analysis.
RPG Life Sciences Limited - Total Assets Trend (2005–2025)
This chart illustrates how RPG Life Sciences Limited's total assets have evolved over time, based on quarterly financial data.
RPG Life Sciences Limited - Asset Composition Analysis
Current Asset Composition (March 2025)
RPG Life Sciences Limited's total assets of Rs7.06 Billion consist of 70.7% current assets and 29.3% non-current assets.
| Asset Category | Amount (INR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs260.00 Million | 4.4% |
| Accounts Receivable | Rs867.60 Million | 13.2% |
| Inventory | Rs929.80 Million | 14.1% |
| Property, Plant & Equipment | Rs1.65 Billion | 25.1% |
| Intangible Assets | Rs227.60 Million | 3.5% |
| Goodwill | Rs0.00 | 0.0% |
Asset Composition Trend (2005–2025)
This chart illustrates how RPG Life Sciences Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market cap of RPG Life Sciences Limited.
Key Asset Composition Facts
- Current vs. Non-Current Assets: RPG Life Sciences Limited's current assets represent 70.7% of total assets in 2025, an increase from 29.2% in 2005.
- Cash Position: Cash and equivalents constituted 4.4% of total assets in 2025, up from 0.3% in 2005.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 3.0% of total assets, an increase from 0.0% in 2005.
- Asset Diversification: The largest asset category is property, plant & equipment at 25.1% of total assets.
RPG Life Sciences Limited Competitors by Total Assets
Key competitors of RPG Life Sciences Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Daihan Pharmaceutical Co.Ltd
KQ:023910
|
Korea | ₩344.02 Billion |
|
Aurobindo Pharma Limited
NSE:AUROPHARMA
|
India | Rs525.46 Billion |
|
China Resources Sanjiu Medical & Pharmaceutical Co Ltd
SHE:000999
|
China | CN¥56.56 Billion |
|
Ningbo Menovo Pharm Co Ltd
SHG:603538
|
China | CN¥4.75 Billion |
|
Zhejiang Xianju Pharmaceutical Co Ltd
SHE:002332
|
China | CN¥7.26 Billion |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365
|
China | CN¥2.26 Billion |
|
Zhejiang Cheng Yi Pharmaceutical Co Ltd
SHG:603811
|
China | CN¥1.69 Billion |
|
Hainan Honz Pharmaceutical Co
SHE:300086
|
China | CN¥1.88 Billion |
RPG Life Sciences Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.40 | 1.97 | 1.92 |
| Quick Ratio | 2.65 | 1.38 | 1.14 |
| Cash Ratio | 0.92 | 0.20 | 0.00 |
| Working Capital | Rs3.44 Billion | Rs1.62 Billion | Rs711.80 Million |
RPG Life Sciences Limited - Advanced Valuation Insights
This section examines the relationship between RPG Life Sciences Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 6.08 |
| Latest Market Cap to Assets Ratio | 0.06 |
| Asset Growth Rate (YoY) | 28.3% |
| Total Assets | Rs6.58 Billion |
| Market Capitalization | $410.49 Million USD |
Valuation Analysis
Below Book Valuation: The market values RPG Life Sciences Limited's assets below their book value (0.06x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: RPG Life Sciences Limited's assets grew by 28.3% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for RPG Life Sciences Limited (2005–2025)
The table below shows the annual total assets of RPG Life Sciences Limited from 2005 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-03-31 | Rs6.58 Billion ≈ $71.14 Million |
+28.26% |
| 2024-03-31 | Rs5.13 Billion ≈ $55.46 Million |
+22.30% |
| 2023-03-31 | Rs4.19 Billion ≈ $45.35 Million |
+21.69% |
| 2022-03-31 | Rs3.45 Billion ≈ $37.27 Million |
+13.59% |
| 2021-03-31 | Rs3.03 Billion ≈ $32.81 Million |
+13.74% |
| 2020-03-31 | Rs2.67 Billion ≈ $28.85 Million |
+6.17% |
| 2019-03-31 | Rs2.51 Billion ≈ $27.17 Million |
-13.74% |
| 2018-03-31 | Rs2.91 Billion ≈ $31.50 Million |
+18.27% |
| 2017-03-31 | Rs2.46 Billion ≈ $26.63 Million |
+20.00% |
| 2016-03-31 | Rs2.05 Billion ≈ $22.19 Million |
+4.23% |
| 2015-03-31 | Rs1.97 Billion ≈ $21.30 Million |
+0.43% |
| 2014-03-31 | Rs1.96 Billion ≈ $21.20 Million |
-4.71% |
| 2013-03-31 | Rs2.06 Billion ≈ $22.25 Million |
+12.50% |
| 2012-03-31 | Rs1.83 Billion ≈ $19.78 Million |
-4.19% |
| 2011-03-31 | Rs1.91 Billion ≈ $20.64 Million |
+14.06% |
| 2010-03-31 | Rs1.67 Billion ≈ $18.10 Million |
-0.33% |
| 2009-03-31 | Rs1.68 Billion ≈ $18.16 Million |
-4.27% |
| 2008-03-31 | Rs1.75 Billion ≈ $18.97 Million |
-14.63% |
| 2007-03-31 | Rs2.05 Billion ≈ $22.22 Million |
-6.36% |
| 2006-03-31 | Rs2.19 Billion ≈ $23.73 Million |
-6.71% |
| 2005-03-31 | Rs2.35 Billion ≈ $25.44 Million |
-- |
About RPG Life Sciences Limited
RPG Life Sciences Limited, an integrated pharmaceutical company, develops, manufactures, and markets branded formulations, generic, and synthetic active pharmaceutical ingredients (APIs) in India and internationally. The company offers synthetic APIs in various therapeutic categories, including immunosuppressants, anti-psychotic, anti-anginal, anthelmintics, anti-convulsant, anti-spasmodic, etc. … Read more